← All Aptevo Therapeutics INC filings

Aptevo Therapeutics INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
APVO
Aptevo Therapeutics INC
10-K: Aptevo Therapeutics Advances Cancer Pipeline, Secures Funding
Aptevo Therapeutics, a clinical-stage biotech, reported positive clinical data for its lead cancer candidates mipletamig and ALG.APV-527, while addressing ongoing financial challenges and securing additional capital.
NASDAQ
APVO
Aptevo Therapeutics INC
10-K: Aptevo Therapeutics Inc. Reports Fiscal Year 2024 Results, Highlights Clinical Progress
Aptevo Therapeutics Inc. releases its 10-K filing, detailing its financial results for fiscal year 2024 and providing updates on its clinical-stage immunotherapy candidates.
NASDAQ
APVO
Aptevo Therapeutics INC
10-K: Aptevo Therapeutics Reports 2023 Financial Results and Provides Business Update
Aptevo Therapeutics, a clinical-stage biotech company, reported a net loss of $17.4 million for 2023, shifting from a net income of $8.0 million in 2022, while advancing its immunotherapy pipeline.